Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990700 | 0.94 | EPHX2 (0.58) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL438428 | 0.93 | ALOX15 (0.62) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL28853476 | 0.92 | ALOX15 (0.61) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL2816525 | 0.90 | LTA4H (0.63) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL9309996 | 0.87 | PTGS1 (0.58) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL20739828 | 0.87 | PTGS1 (0.58) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL891275 | 0.83 | TOP2A (0.67) | EPHX2TOP2ALTA4HALOX15TRPV1 | |
| SCHEMBL20739827 | 0.82 | POLM (0.62) | EPHX2TOP2ATRPV1MEN1TP53 | |
| SCHEMBL26090058 | 0.82 | POLM (0.62) | EPHX2TOP2ATRPV1MEN1TP53 | |
| SCHEMBL2815571 | 0.82 | ALOX15 (0.64) | EPHX2TOP2ALTA4HALOX15TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467398-B1 | TRPC4 INHIBITORS AND USES THEREOF | POSEIDA THERAPEUTICS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | EPHX2 4306/4885TOP2A 4874/4885LTA4H 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.